A5005364932- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Head and Neck Cancer Studies
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Cancer survivorship and care
- Occupational and environmental lung diseases
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Multiple and Secondary Primary Cancers
- Head and Neck Surgical Oncology
- Esophageal and GI Pathology
- Childhood Cancer Survivors' Quality of Life
- Cancer-related cognitive impairment studies
- Pleural and Pulmonary Diseases
- HER2/EGFR in Cancer Research
- Salivary Gland Tumors Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- Vascular Tumors and Angiosarcomas
- Cancer therapeutics and mechanisms
- Advanced Radiotherapy Techniques
- Sinusitis and nasal conditions
IRCCS Humanitas Research Hospital
2007-2023
Humanitas University
2008-2022
Istituti di Ricovero e Cura a Carattere Scientifico
2009-2022
Fondazione Humanitas per la Ricerca
2004-2018
Humanitas (United States)
2015
Weatherford College
2007
Fondazione IRCCS Istituto Nazionale dei Tumori
1996-2003
Rationale: Screening for lung cancer with low-dose spiral computed tomography (LDCT) has been shown to reduce mortality by 20% compared screening chest X-ray (CXR) in the National Lung Trial, but uncertainty remains concerning efficacy of LDCT a community setting.Objectives: To explore effect on no screening. Secondary endpoints included incidence, stage, and resectability rates.Methods: Male smokers 20+ pack-years, aged 60 74 years, underwent baseline CXR sputum cytology examination...
Purpose This multicenter, phase II clinical study was conducted to evaluate the activity of combination pemetrexed and carboplatin in patients with malignant pleural mesothelioma (MPM). Patients Methods Chemotherapy-naive measurable disease adequate organ function, who were not eligible for curative surgery, received 500 mg/m 2 area under plasma concentration-time curve 5 mg/mL/min, administered intravenously every 21 days. All folic acid vitamin B 12 supplementation. Pemetrexed provided...
Gefitinib ('Iressa', ZD1839) is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated antitumour activity and favourable tolerability in Phase II studies. We investigated whether EGFR expression levels could predict for response to gefitinib patients with advanced non-small-cell lung cancer (NSCLC), who received (250 mg day(-1)) as part of a worldwide compassionate-use programme. Tissue samples were analysed by immunohistochemistry assess...
Pemetrexed-cisplatin chemotherapy is the standard of care in first-line treatment unresectable malignant pleural mesothelioma (MPM). Second-line cytotoxic therapy considered for a growing group patients, but optimal has not been defined to date. Gemcitabine and vinorelbine have shown activity setting. The objective this study was evaluate toxicity gemcitabine-vinorelbine combination pemetrexed-pretreated patients with MPM.From January 2004 September 2006, 30 consecutive who were pretreated...
Abstract Background To report acute toxicity, initial outcome results and planning therapeutic parameters in radiation treatment of advanced lung cancer (stage III) with volumetric modulated arcs using RapidArc (RA). Methods Twenty-four consecutive patients were treated RA. All showed locally non-small cell stage IIIA-IIIB large volumes (GTV:299 ± 175 cm 3 , PTV:818 206 ). Dose prescription was 66Gy 33 fractions to mean PTV. Delivery performed two partial a 6 MV photon beam. Results From...
Abstract Lessons Learned NGR-hTNF was safely combined with doxorubicin, showing a promising antitumor activity in unselected patients relapsed small cell lung cancer. Similar observed platinum-sensitive and platinum-resistant patient cohorts. Background Relapsed cancer (SCLC) have limited treatment options poor outcomes. is vascular-targeting agent, which increases intratumoral chemotherapy penetration T-lymphocyte infiltration. Methods Twenty-eight relapsing after at least one...
To compare the surgical and survival outcomes of patients undergoing primary debulking surgery (PDS) versus neoadjuvant chemotherapy (NACT) plus interval (IDS) for advanced epithelial ovarian cancer (EOC).Consecutive managed EOC since 2009 were matched through a propensity score analysis, defined as probability woman having PDS or NACT IDS.The study group consisted 100 propensity-matched women receiving IDS. Groups resulted homogeneous in terms baseline characteristics pathologic findings....
The aim of this study was to evaluate the activity and safety oxaliplatin/5-fluorouracil-based chemo-radiotherapy in patients with not radically resectable locally advanced esophageal cancer. Fifty-nine adeno or squamous-cell carcinoma received oxaliplatin (60 mg/m2), leucovorin (20 mg/m2 on days 1,8,15,29,36,43,50,57) followed by continuous infusion fluorouracil (200 per day 1–22 29–64) radiotherapy (1.8 Gy daily fractions a total dose 45 Gy, from 29 64). When feasible, surgery scheduled...
The predictive role in terms of pathological response and prognostic biomarkers such as GST-π, p53, bcl-2 bax expression, immuno-histochemically detected, the S-phase cell fraction, autoradiographically determined thymidine labeling index (TLI), were investigated within a prospective randomized phase III clinical trial on squamous-cell carcinoma oral cavity, including surgery or primary chemotherapy (PCT), which foresaw determination biological markers. Pathological was defined achievement...
The use of immune checkpoint inhibitors (ICIs) for treating several types cancer is increasing, but they may be associated with immune-related adverse events (irAEs). Pancreatitis a rare irAE, mostly responsive to steroid treatment. There are no published data on the management steroid-refractory ICI-induced pancreatitis. Rituximab has shown efficacy in setting relapsing non-ICI-induced autoimmune However, its not been tested immunotherapy-related Here, we present case patient pancreatitis...